A complex picture of both risks and potential benefits emerges from new data on antidepressant use during pregnancy.
A recent meta-analysis and a large-scale population-based study have provided new data on the associations between antidepressant use during pregnancy and various health outcomes for mothers and children. The studies, which used different methodologies and examined different classes of antidepressants, present a complex picture of both risks and potential benefits.
Meta-Analysis: Antidepressants, Autism, and ADHD
A meta-analysis of 37 studies, involving over 600,000 pregnant women who took antidepressants and nearly 25 million who did not, was published in The Lancet Psychiatry. The analysis found that after adjusting for genetic, familial, and other confounding factors, antidepressant exposure during pregnancy had little to no association with autism and ADHD in children.
Initial data showed increased risks, but these weakened or disappeared when other factors were considered. For the tricyclic antidepressants amitriptyline and nortriptyline, an association with ADHD remained, though causality was not established. The authors noted that untreated depression poses risks to both mother and child.
Population Study: SSRIs, Gestational Diabetes, and Newborn Adaptation
A separate population-based study focused on Selective Serotonin Reuptake Inhibitors (SSRIs). This collaborative research between the Research Centre for Child Psychiatry at the University of Turku, Finland, and Columbia University in New York analyzed national registry data from Finland, covering over 1.27 million children born between 1996 and 2018.
The study compared mothers who used SSRIs during pregnancy with control groups, including women diagnosed with depression who did not use antidepressants, and women who discontinued SSRI use before pregnancy. Sibling comparisons were employed to account for hereditary and environmental factors. The research aimed to differentiate between risks attributable to the medication and those attributable to maternal depression and its severity.
Key FindingsIncreased Risks Associated with SSRI Use:
- Gestational Diabetes: An increased risk was observed compared to women with depression who did not use medication.
- Newborn Adaptation Issues: Infants exposed to SSRIs in utero had a higher risk of lower Apgar scores at 1 and 5 minutes, breathing problems, and the need for neonatal care or neonatal intensive care unit (NICU) treatment. These effects were found to be independent of maternal depression. No increased risk of major congenital malformations was found.
"SSRI use appears to offer protection against preterm birth risks associated with depression but has independent effects on the early adaptation of newborns."
Decreased Risks Associated with SSRI Use:
- SSRI use was associated with a lower risk of preterm birth, low birth weight, and caesarean sections.
- When comparing women who continued SSRI use during pregnancy to those who discontinued it before pregnancy, continued use was linked to a lower risk of late preterm birth and low birth weight.
Interpretation and Commentary
Docent Heli Malm, the lead author of the population study, stated that the results highlight the importance of individualized treatment decisions during pregnancy. Malm indicated that SSRI use appears to offer protection against preterm birth risks associated with depression but has independent effects on the early adaptation of newborns. Malm emphasized the need for close monitoring of both pregnancy progress and newborn health. Further research is required to clarify the association with gestational diabetes, including potential cause-and-effect relationships and underlying biological mechanisms.